An analysis of quiescent CML stem cells, persisting despite TKI therapy, identified markers of inflammation, including overexpression of IL-6, TGF-β, and Tumour Necrosis Factor alpha (TNF-α) [46,47,56,57]. Here, IL6 is linked to chronic myelogenous leukemia, BCR-ABL1 positive.